Biotechnology Archives - InvestorWire (IW)

Tuesday Dec 03, 2024 - 3:41 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’

Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The platform addresses challenges presented by untargetable and untreatable metastatic diseases…

Tuesday Nov 19, 2024 - 2:30 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its…

Tuesday Oct 29, 2024 - 12:51 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to…

Thursday Oct 24, 2024 - 12:53 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced an upcoming meeting with U.S. Food and Drug Administration (“FDA”) leadership. The focus is to discuss Clene’s CNM-Au8® biomarker and related clinical and survival data…

Tuesday Oct 22, 2024 - 2:30 pm

InvestorNewsBreaks – Astiva Health Stands out in Upward Trend for Quality Medicare Advantage Plans

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities. A recent article discusses the transformation over the past two decades of Medicare Advantage from a niche option into a primary choice for millions of seniors across the U.S. In this evolving market, companies like Astiva Health are stepping up to meet the growing demand for…

Monday Oct 14, 2024 - 3:29 pm

InvestorNewsBreaks – Astiva Health Providing Standout Option During Medicare Open Enrollment Period

Astiva is a leading provider of personalized and comprehensive healthcare solutions to diverse communities. “Medicare open enrollment for 2024-2025 begins on Oct. 15, 2024, and closes on Dec. 7, 2024, as noted in a recent Medicare Advocates article… Astiva Health provides a standout option during this critical enrollment period, offering a health plan designed to meet the specialized needs of its members,” a recent article…

Wednesday Sep 25, 2024 - 9:52 am

InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing Guys and St. Thomas Hospital, a London-based hospital with a leading oncology clinic and cell therapy clinical team, as a new site in the ACHIEVE UK Trial. The site opened in September 2024, expediting the progression of the trial timelines and increasing the…

Friday Sep 20, 2024 - 2:20 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug…

Wednesday Sep 18, 2024 - 2:16 pm

InvestorNewsBreaks – Astiva Health Setting New Standard for Healthcare Delivery to Aging Population

Astiva Health is a leading healthcare provider specializing in delivering personalized and comprehensive solutions to diverse communities. The company is launching a comprehensive community outreach initiative to improve wellness and healthcare access for seniors across Southern California. “This initiative represents a significant expansion of Astiva’s commitment to addressing the unique needs of its growing Medicare Advantage Prescription Drug (‘MAPD’) member base. Astiva Health is leveraging…

Tuesday Sep 10, 2024 - 9:49 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”). The meeting focused on the company's development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorder. According to the announcement,…

Tuesday Sep 03, 2024 - 1:16 pm

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The meeting supported the advancement of Lomecel-B(TM), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (“ELPIS II”) for hypoplastic left heart syndrome…

Tuesday Sep 03, 2024 - 11:32 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else…

Friday Aug 30, 2024 - 2:45 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer…

Friday Aug 30, 2024 - 2:15 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway…

Friday Aug 30, 2024 - 2:15 pm

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), recently welcomed four seasoned professionals to its executive team. “Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases.…

Thursday Aug 29, 2024 - 9:26 am

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Partners with Digital eCommerce Experts to Grow Online Presence

Safety Shot (NASDAQ: SHOT), a wellness company, is partnering with VENDO, a fully customizable, multipurpose eCommerce platform. Safety Shot has created the world's first alcohol detoxifier that reduces blood alcohol content by supporting its metabolism in as little as 30 minutes. According to the announcement, VENDO is an Amazon expert and Walmart marketplace wizard that works directly with brands to drive strategic and sustainable growth…

Monday Aug 26, 2024 - 9:43 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space spanning more than two decades. His experience includes building and…

Thursday Aug 22, 2024 - 2:30 pm

InvestorNewsBreaks – PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare…

Thursday Aug 22, 2024 - 11:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at 12 p.m. ET on Aug. 26, 2024. During the webcast,…

Wednesday Aug 21, 2024 - 1:29 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the agreement, Aditxt, through its wholly owned subsidiary Adivir Inc., will…

Wednesday Aug 21, 2024 - 9:28 am

InvestorNewsBreaks – GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor

GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share as part of a registered direct offering. The company will…

Monday Aug 19, 2024 - 2:02 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive data from two preclinical studies. The data support the potential for the Next Generation irinotecan (“NGC-Iri”), the prodrug of SN-38, which is the active anticancer metabolite of irinotecan, to have improved efficacy and a better side effect profile compared with…

Monday Aug 19, 2024 - 9:29 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company continues to move forward on developing and advancing its lead candidate, ONP-002, for the treatment of concussion. Specifically, the update noted that phase 2 human trials are slated to begin…

Friday Aug 16, 2024 - 3:03 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part…

Thursday Aug 15, 2024 - 10:13 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and…

Thursday Aug 15, 2024 - 9:34 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from…

Wednesday Aug 14, 2024 - 1:28 pm

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), recently had its price target set at $21.00. The price target was issued by Jason Kolbert from EF Hutton on August 13, 2024. At the time of the announcement, Annovis Bio was trading at $7.87. “The overall price target consensus is at $26.00 with…

Wednesday Aug 14, 2024 - 10:41 am

InvestorNewsBreaks — NextPlat Corp. (NASDAQ: NXPL), Progressive Care (RXMD) Release Q2 2024 Financial Results Showing 474% Revenue Increase

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a…

Wednesday Aug 14, 2024 - 9:57 am

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and restated in July 2024, with a targeted close for later…

Wednesday Aug 14, 2024 - 9:20 am

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting its financial results for the first quarter 2025, or the period ended June 30, 2024. The report also included a status update on the company’s pipeline, including fasedienol for the acute treatment of social anxiety…

Wednesday Aug 14, 2024 - 9:00 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Stable Across Wide Range of Temps

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, recently completed the synthesis of its ONP-002 drug batch for its upcoming planned phase 2 clinical trial. Consequently, the company is reporting that ONP-002, its lead candidate for treating concussion, is stable across a wide temperature range, thus eliminating the need for cumbersome cold storage during transport…

Tuesday Aug 13, 2024 - 12:37 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders' meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 and B-2 convertible preferred stock.In addition, a proposed Equity Line…

Tuesday Aug 13, 2024 - 11:12 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Expansion of Live-Cell Tumor Platform Applications

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts…

Friday Aug 09, 2024 - 11:36 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a securities purchase agreement with certain institutional investors. The agreement outlines a registered direct offering for the purchase and sale of 1,130,189 shares of common stock or common stock equivalents for $1.06 per share. Proceeds from the offering are projected to total approximately…

Friday Aug 09, 2024 - 10:26 am

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the results for its first fiscal quarter of 2025, the period ended on June 30, 2024. According to the report, highlights for the company included the company’s collaboration with Pablo Arbelaez, a renowned AI expert and researcher, in the development of the phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation…

Thursday Aug 08, 2024 - 1:17 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was featured in the latest episode of the BioMedWire Podcast, which is part of a sustained effort by IBN (Investor Brand Network) to provide specialized content distribution via widespread syndication channels. During the episode, Clene CEO and president Rob Etherington talks with IBN’s Carmel…

Thursday Aug 08, 2024 - 12:34 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 multinational study for the CYB003 program in late summer of…

Thursday Aug 08, 2024 - 11:44 am

InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. The announcement…

Thursday Aug 08, 2024 - 9:15 am

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Passes FDA-Required Cardiotoxicity Testing

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, is reporting that ONP-002, its lead candidate for treating concussion, has successfully completed a study indicating the substance does not cause cardiotoxicity. Testing pharmaceuticals on cardiac receptors to ensure that they do not show any causes of electrical malformations is required by the U.S. Food and Drug…

Wednesday Aug 07, 2024 - 2:50 pm

InvestorNewsBreaks – Scorpius Holdings Inc. (NYSE American: SCPX) Releases Public Offering Pricing for Public Offering

Scorpius Holdings (NYSE American: SCPX), an integrated contract-development and manufacturing organization (CDMO), has announced the pricing of an underwritten public offering. The offering is comprised of 12,500,000 shares of common stock or prefunded warrants. Each share of common stock or prefunded warrant is offered at $1. According to the announcement, the company has estimated gross proceeds of approximately $12,500,000, before underwriting discounts and offering expenses…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions